ライフサイエンスコーパス: galantamine

1 pha, IL-6 and HMGB-1) were all attenuated by galantamine.

2 inesterase inhibitors, such as donepezil and galantamine.

3 different modes of action for donepezil and galantamine.

4 ent in patients receiving 16 or 24 mg/day of galantamine.

5 nicotine-evoked responses occurred at 1 muM galantamine.

6 erminant of the therapeutic effectiveness of galantamine.

7 30 min prior to each insult with vehicle or galantamine (4 mg/kg, i.p.).

8 bed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) increase action potential-depen

9 ase who were randomly assigned to placebo or galantamine (8, 16, or 24 mg/day) were analyzed.

10 Galantamine, a centrally acting acetylcholinesterase inh

11 chnique was used to determine the effects of galantamine, a cholinesterase inhibitor and a nicotinic

12 Galantamine, a cholinesterase inhibitor used in Alzheime

13 alysis was conducted to assess the impact of galantamine, a cholinesterase inhibitor with nicotinic-r

14 Here, we demonstrate that galantamine, a reversible and centrally acting AChE inhi

15 and human cerebral cortical slices, 1 microM galantamine, acting as a nicotinic APL, increased gamma-

16 Likewise, 1 microM galantamine, acting as an APL on presynaptically located

17 We conclude that galantamine activates the muscle-type ACh receptor by in

18 combination with atropine, a single dose of galantamine administered before or soon after acute expo

19 Acute galantamine administration (5.0 mg/kg, i.p.) attenuated

20 Galantamine administration also attenuated the reinstate

21 ever, there are no studies examining whether galantamine administration modulates nicotine self-admin

22 ts were designed to determine the effects of galantamine administration on nicotine taking and reinst

23 del, animals received direct implantation of galantamine alone, empty PLGA particles, or PG.

24 Galantamine also ameliorated diabetes-induced kidney inj

25 signed to examine the efficacy and safety of galantamine, an acetylcholinesterase inhibitor that also

26 Here, we studied the effects of galantamine, an approved cholinergic drug (for Alzheimer

27 0 Amaryllidaceae alkaloids (AmAs), including galantamine, an FDA-approved treatment for Alzheimer's d

28 183 of 207 patients (88%) who received galantamine and 177 of 200 (89%) who received placebo ha

29 Forty-two subjects were assigned to galantamine and 44 were assigned to placebo.

30 The combined cerebral metabolic effects of galantamine and citalopram suggest, consistent with prec

31 ved) by 1.9 (95% CI -0.1 to 3.9) points with galantamine and decreased (worsened) by 3.0 (-5.6 to -0.

32 Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3

33 The brain-to-plasma ratio for galantamine and donepezil, respectively, ranges from 1.2

34 geted compounds obtained by linking together galantamine and memantine.

35 ad similar effects on receptor activation by galantamine and nicotinic agonists, suggesting that the

36 d previously for the nonselective nAChR PAMs galantamine and physostigmine at the canonical alpha-gam

37 ts performed in the simultaneous presence of galantamine and various nicotinic ligands showed that ch

38 own efficacy, including dextromethorphan and galantamine, and new drugs such as muscle relaxants that

39 e general features of receptor activation by galantamine are similar to that in the presence of ACh.

40 lkaloids, such as the Alzheimer's medication galantamine, are complex plant secondary metabolites wit

41 choline) was not affected by the presence of galantamine at concentrations up to 100 microm.

42 Thus, a galantamine-based therapy emerges as an effective and sa

43 r, there is also evidence demonstrating that galantamine can activate the nicotinic ACh receptor or m

44 Galantamine can be started and used safely in elderly pa

45 erlie the allocation of attention or whether galantamine changed the mapping from those beliefs to su

46 for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI, 0.67-1.35).

47 ne compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI, 0.83-1.27).

48 Galantamine-containing PLGA particles (PG) were synthesi

49 Studies of direct activation by galantamine demonstrated that this ligand is a low-effic

50 acetylcholinesterase (AChE) in complex with galantamine derivatives.

51 Galantamine did not compete for radioligand binding to t

52 In addition, galantamine did not reduce the initial rate of binding f

53 These results demonstrate that galantamine does not interfere with the occupation of th

54 patients 2 months after titration to a 24 mg galantamine dose.

55 Galantamine doses between 1.5 and 5 mg/kg are appropriat

56 the highest inhibition against AChE (2.44 mg galantamine equivalent/g) and the water extracts of A. i

57 part were the best BChE inhibitors (4.31 mg galantamine equivalent/g).

58 p analyses revealed that the subjects taking galantamine exhibited significant improvements on the WA

59 The efficacy of galantamine for cognitive impairments was evaluated with

60 Clearance of galantamine from the brain is in general faster that don

61 The allosterically potentiating ligand galantamine (Gal) modulates nicotinic cholinergic recept

62 168 of 207 (81%) patients in the galantamine group and 161 of 200 (81%) in the placebo gr

63 Eight patients (4%) in the galantamine group and 21 patients (11%) in the placebo g

64 eas patients treated with 16 or 24 mg/day of galantamine had no change in total Neuropsychiatric Inve

65 tiation was blocked by mecamylamine, whereas galantamine had no effect on these measures in the absen

66 The efficacy of galantamine has been shown in patients with mild, modera

67 Galantamine has recently been shown to reverse nicotine

68 Trials of galantamine, hydrocortisone, IgG, valganciclovir, isopri

69 Galantamine improved cognitive function but failed to si

70 In addition, galantamine improved the functional state of mice with A

71 Previous research demonstrated that galantamine improves functional outcomes in SCI models.

72 rovide insights into the mechanisms by which galantamine improves glycemic control and attenuates DN

73 onepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE.

74 values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous

75 Galantamine is a licenced treatment for AD but supplies

76 Galantamine is a rather weak acetylcholinesterase (AChE)

77 Galantamine is an acetylcholinesterase inhibitor that al

78 Galantamine is known to sensitize nAChRs to activation b

79 Therefore, at 1 microM, galantamine is likely to increase facilitation of synapt

80 Behaviorally, galantamine led to a greater influence of probabilistic

81 These results demonstrate that galantamine-loaded PLGA nanoparticles provide superior t

82 op and evaluate the therapeutic potential of galantamine-loaded poly(lactic-co-glycolic acid) (PLGA)

83 ive impairments in mice, which suggests that galantamine may function to prevent relapse in human smo

84 Study results suggest that galantamine may have selective benefits for aspects of p

85 maries provide some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine,

86 me setting were randomly assigned to receive galantamine (n=207), titrated initially to 24 mg/day, or

87 Doses of galantamine needed to protect guinea pigs fully against

88 Neither galantamine nor levodopa, which elevate acetylcholine an

89 icant between-group differences in favour of galantamine occurred for the SIB domains of memory (p=0.

90 We investigated the effects of galantamine on glycemic control and development of diabe

91 nicotine self-administration, no effects of galantamine on nausea/malaise as measured by pica were n

92 No significant effects of galantamine on sucrose self-administration or sucrose re

93 Moreover, the effects of galantamine on sucrose-maintained responding and sucrose

94 inhibitor and nicotinic receptor modulator, galantamine, on the cerebral metabolic response to the s

95 Three donepezil, two galantamine, one rivastigmine, and two memantine trials,

96 adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95% CI, 0.83-1.86)

97 rt 3 compared memantine with rivastigmine or galantamine only.

98 We administered tacrine, galantamine or memantine to mouse cerebral cortical cult

99 In SH-SY5Y cells, galantamine potentiated nicotine-evoked increases in int

100 irenz (EFV), acetaminophen, mirtazapine, and galantamine) prescribed for indications unrelated to cho

101 challenge with the cholinesterase inhibitor galantamine (Reminyl).

102 Galantamine (Reminyl; Janssen Pharmaceutica, Titusville,

103 lcholinesterase inhibitor and Alzheimer drug galantamine represents the prototypical allosteric ligan

104 roved to treat Alzheimer disease (donepezil, galantamine, rivastigmine, and memantine) improved score

105 king were also examined to determine whether galantamine's effects generalized to other reinforced be

106 Galantamine significantly reduced food intake, body weig

107 of brain AChE inhibition, 3-15 times higher galantamine than donepezil doses are needed.

108 Unlike galantamine, the acetylcholinesterase inhibitors rivasti

109 Galantamine therapy was associated with reduced emergenc

110 this study, we have examined the ability of galantamine to directly activate the muscle-type nicotin

111 ork was to enhance the transportation of the galantamine to the brain via ascorbic acid grafted PLGA-

112 acebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints

113 Galantamine treatment alone increased metabolism in the

114 uding at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients with AD, PD, or DL

115 Galantamine treatment significantly decreased bronchoalv

116 In contrast, during galantamine treatment, citalopram increased metabolism i

117 epezil with those prescribed rivastigmine or galantamine using the new-user design.

118 d memantine with donepezil, rivastigmine, or galantamine using the prevalent new-user design.

119 High-dose galantamine was associated with a significant reduction

120 In preventing the lethality of nerve agents, galantamine was far more effective than pyridostigmine,

121 In general, safety analyses revealed that galantamine was well tolerated.

122 In addition, galantamine, which is both an inhibitor of AChE and an a

123 m hippocampal slices was also potentiated by galantamine, with an additional component attributable t